Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
- (-) Clean Energy (20)
- (-) Nuclear Science and Technology (1)
- Advanced Manufacturing (2)
- Biology and Environment (20)
- Computational Engineering (1)
- Computer Science (2)
- Fusion and Fission (1)
- Isotopes (4)
- Materials (26)
- Materials for Computing (5)
- National Security (19)
- Neutron Science (9)
- Quantum information Science (1)
- Supercomputing (25)
News Type
News Topics
- (-) Biomedical (5)
- (-) Clean Water (2)
- (-) Cybersecurity (5)
- (-) Machine Learning (4)
- (-) Polymers (5)
- (-) Quantum Science (1)
- 3-D Printing/Advanced Manufacturing (39)
- Advanced Reactors (5)
- Artificial Intelligence (4)
- Big Data (2)
- Bioenergy (16)
- Biology (6)
- Biotechnology (2)
- Buildings (14)
- Chemical Sciences (10)
- Climate Change (8)
- Composites (5)
- Computer Science (11)
- Coronavirus (8)
- Critical Materials (5)
- Decarbonization (18)
- Energy Storage (37)
- Environment (19)
- Exascale Computing (2)
- Fossil Energy (1)
- Frontier (1)
- Fusion (3)
- Grid (15)
- High-Performance Computing (2)
- Isotopes (3)
- Materials (19)
- Materials Science (13)
- Mathematics (1)
- Mercury (2)
- Microscopy (5)
- Molten Salt (1)
- Nanotechnology (5)
- National Security (5)
- Net Zero (2)
- Neutron Science (9)
- Nuclear Energy (13)
- Partnerships (8)
- Physics (3)
- Renewable Energy (1)
- Security (5)
- Simulation (1)
- Space Exploration (2)
- Summit (3)
- Sustainable Energy (30)
- Transformational Challenge Reactor (3)
- Transportation (27)
Media Contacts
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.